Home › Peptides › Cagrilintide + Semaglutide
Cagrilintide + Semaglutide dosage and protocol
A combination blend of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist) studied for synergistic effects on metabolic research and weight management.
- Vial size: 10 mg
- Reconstitution: 3 mL bacteriostatic water
- Concentration: 3.33 mg/mL
- Administration: subcutaneous
Research areas
- Metabolic Research
- Weight Management
- Glucose Regulation
- Appetite Control
Quick start
- Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg vial → 3.33 mg/mL total peptide
- Typical dose: 0.25 mg of each peptide weekly, escalating every 4 weeks to 2.4 mg of each
- Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33 mcg total (≈16.7 mcg each); 0.25 mg each = 15 units, 0.5 mg each = 30 units, 1.0 mg each = 60 units on a U-100 syringe
- Storage: Lyophilized at −20°C; refrigerate after mixing and use within 28 days
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Weeks 1–4 | 250 mcg each peptide (0.25 mg) | Once weekly | 0.15 mL |
| Weeks 5–8 | 500 mcg each peptide (0.5 mg) | Once weekly | 0.30 mL |
| Weeks 9–12 | 1000 mcg each peptide (1.0 mg) | Once weekly | 0.60 mL |
| Weeks 13–16 | 1700 mcg each peptide (1.7 mg) | Once weekly | 1.02 mL |
| Week 17+ | 2400 mcg each peptide (2.4 mg) | Once weekly | 1.44 mL |
How it works
This combination pairs cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 receptor agonist. Semaglutide mimics the gut hormone GLP-1: it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and acts on hypothalamic and hindbrain centers to reduce appetite. Cagrilintide activates amylin and calcitonin receptors, particularly in the area postrema, increasing satiety and further slowing gastric emptying. The two hormones act through different receptors and partly different brain circuits, so their appetite-suppressing effects are additive. Semaglutide alone is FDA-approved as Ozempic (type 2 diabetes and cardiovascular risk reduction), Rybelsus (oral, type 2 diabetes) and Wegovy (chronic weight management, cardiovascular risk reduction in people with obesity). The fixed-dose combination, known as CagriSema, has been studied at 2.4 mg of each peptide once weekly in phase 2 and phase 3 trials in people with obesity, with or without type 2 diabetes. In those trials, the combination produced greater weight loss than either component alone, along with improvements in glycemic control. Gastrointestinal effects were the most common adverse events. The combination is investigational; its regulatory status should be checked, and the research blend here is not the same as a pharmaceutical product.
Reconstitution steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe
- Inject slowly down the vial wall; avoid foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label with date and refrigerate at 2–8°C, protected from light; use within 30 days
Storage
Store lyophilized at -20°C. Refrigerate after reconstitution. Use within 28 days.
Important notes
- Research use only.
- Gradual escalation important.
- Combines two mechanisms for enhanced metabolic effects.
Supplies
- Cagrilintide + Semaglutide blend vial (10mg)
- 3 mL bacteriostatic water
- Insulin syringes (U-100)
- Alcohol swabs
- Sharps container
Related peptides
Calculate your Cagrilintide + Semaglutide dose in syringe units